All News

NUV-422 has demonstrated favorable blood-brain barrier penetration in patients with high-grade gliomas.

In episode 3 of a 4-part small cell lung cancer podcast series, Wade Iams, MD, highlights practical considerations for treating patients with small cell lung cancer, including managing toxicities and the impact of treatment on a patient’s quality of life.

Nina Shah, MD, discusses the biggest news from the FDA for multiple myeloma in the past year.

Patients with triple-class relapsed/refractory multiple myeloma treated with ciltacabtagene autoleucel saw a greater survival benefit over physician's choice of treatment.

Abatacept can now be used for the prevention of acute graft-versus-host disease following its approval by the FDA.

Most subgroups of patients with relapsed or refractory, heavily pretreated multiple myeloma showed durable responses at the 2-year follow-up to the CARTITUDE-1 trial.

Patients with heavily pretreated relapsed/refractory multiple myeloma achieved promising benefit in terms of cytokine release syndrome mitigation via double cycle 1 step-up dosing for cevostamab.

Deep responses were seen with single infusion ciltacabtagene autoleucel for heavily pretreated patients with multiple myeloma who were refractory to lenalidomide.

When asked about abstracts he thinks have the greatest potential to impact the standard of care in myeloma, Rafael Fonseca, MD, looked to emerging cellular therapies, specifically ciltacabtagene autoleucel for the treatment of heavily pretreated disease.

CancerNetwork® looks back on some of the promising, ongoing pieces of clinical research within the breast cancer space from 2021.

Second-line treatment of lisocabtagene maraleucel demonstrated improved quality of life in patients with large B-cell lymphoma.

Maintenance oral azacitidine produced a sustained survival benefit over placebo for patients with acute myeloid leukemia in first remission.

Susan M. O’Brien, MD, discussed the emergence of noncovalent BTK inhibitors for treating chronic lymphocytic leukemia.

Jennifer A. Woyach, MD, spoke about the results of a study conducted in elderly patients treated with an ibrutinib-containing regimen for chronic lymphocytic leukemia at 55 months of follow-up.

Patients with previously untreated diffuse large B-cell lymphoma experienced promising responses after being treated with tafasitamab-cxix and lenalidomide plus rituximab, cyclophosphamide, doxorubicin, vincristin, and prednisone.

Data from a retrospective head-to-head analysis of pacritinib vs ruxolitinib showed that the former was more favorable in terms of symptom response for patients with myelofibrosis and thrombocytopenia.

The combination of high-frequency and low-dose acalabrutinib and rituximab demonstrated a 100% overall response rate in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Acalabrutinib produced positive quality-adjusted survival benefits over other treatment options for patients with relapsed/refractory chronic lymphocytic leukemia.

A post-hoc analysis of a phase 3 trial presented at 2021 ASH indicate that acalabrutinib may be favorable in terms of toxic burden and cardiovascular-related events when compared against ibrutinib for treating chronic lymphocytic leukemia.

Patients with cytopenic myelofibrosis produced a tolerable safety profile when receiving treatment with pacritinib.

A phase 2 study has begun recruiting patients with relapsed/refractory acute myeloid leukemia to test the efficacy of magrolimab.

Patients with relapsed/refractory multiple myeloma continue to experience robust and durable benefit from treatment with ciltacabtagene autoleucel.

Patients with polycythemia vera who have controlled hematocrit and elevated white blood counts can have increased risk of thrombotic events.

YTB323 led to a promising safety profile and encouraging efficacy outcomes for adult patients with relapsed/refractory diffuse large B-cell lymphoma.

Patients with relapsed/refractory t(11;14) multiple myeloma appeared to benefit from treatment with venetoclax at a dose of 400 mg or 800 mg plus daratumumab/dexamethasone.

Luciano Costa, MD, PhD, spoke about the primary end point analysis for the MASTER trial examining daratumumab, carfilzomib, lenalidomide, and dexamethasone in multiple myeloma.

Patients with low-risk myelodysplastic syndrome saw more durable responses and higher tolerability when taking luspatercept-aamt compared with the placebo.

Daratumumab plus lenalidomide, bortezomib, and dexamethasone followed by transplant continues to show superior efficacy vs triplet therapy alone at a 2-year follow-up to the GRIFFIN trial.

A post hoc analysis showed that a dose reduction of selinexor yielded higher safety and efficacy for patients with multiple myeloma.

Patients with high-risk large B-cell lymphoma saw durable responses when treated with axicabtagene ciloleucel.